EMAIL THIS PAGE TO A FRIEND

Journal of hepatology

Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation.


PMID 25315650

Abstract

Ischemia-reperfusion (IR) of liver results in hepatocytes (HP) and sinusoidal endothelial cells (LSEC) irreversible damage. Ischemic preconditioning protects IR damage upon adenosine A2a receptor (A2aR) stimulation. Understanding the phenotypic changes that underlie hepatocellular damage and protection is critical to optimize strategies against IR. The proteome of HP and LSEC, isolated from sham or IR exposed mice, receiving or not the A2aR agonist CGS21680 (0.5mg/kg b.w.), was analyzed by 2-D DIGE/MALDI-TOF. We identified 64 proteins involved in cytoprotection, regeneration, energy metabolism and response to oxidative stress; among them, 34 were associated with IR injury and A2aR protection. The main pathways, downregulated by IR and upregulated by CGS21680 in HP and LSEC, were related to carbohydrate, protein and lipid supply and metabolism. In LSEC, IR reduced stress response enzymes that were instead upregulated by CGS21680 treatment. Functional validation experiments confirmed the metabolic involvement and showed that inhibition of pyruvate kinase, 3-chetoacylCoA thiolase, and arginase reduced the protection by CGS21680 of in vitro hypoxia-reoxygenation injury, whereas their metabolic products induced liver cell protection. Moreover, LSEC, but not HP, were sensitive to H2O2-induced oxidative damage and CGS21680 protected against this effect. IR and A2aR stimulation produces pathological and protected liver cell phenotypes, respectively characterized by down- and upregulation of proteins involved in the response to O2 and nutrients deprivation during ischemia, oxidative stress, and reactivation of aerobic energy synthesis at reperfusion. This provides novel insights into IR hepatocellular damage and protection, and suggests additional therapeutic options.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

01700
Acrylamide, purum, ≥98.0% (GC)
C3H5NO
01696
Acrylamide, for Northern and Southern blotting, powder blend
C3H5NO
08267
Acrylamide, certified reference material, TraceCERT®
C3H5NO
23701
Acrylamide, analytical standard
C3H5NO
01697
Acrylamide solution, 40% in H2O, for molecular biology
C3H5NO
A5508
Adenosine 5′-phosphosulfate sodium salt, ≥85%
C10H14N5O10PS
A3678
Ammonium persulfate, for molecular biology, for electrophoresis, ≥98%
H8N2O8S2
A9164
Ammonium persulfate, for molecular biology, powder, ≥98%
H8N2O8S2
A7460
Ammonium persulfate, BioXtra, ≥98.0%
H8N2O8S2
09913
Ammonium persulfate, BioUltra, for molecular biology, ≥98.0% (RT)
H8N2O8S2
N7502
DL-Norvaline
C5H11NO2
T9281
N,N,N′,N′-Tetramethylethylenediamine, BioReagent, suitable for electrophoresis, ~99%
C6H16N2
T7024
N,N,N′,N′-Tetramethylethylenediamine, BioReagent, for molecular biology, ≥99% (GC)
C6H16N2
411019
N,N,N′,N′-Tetramethylethylenediamine, ≥99.5%, purified by redistillation
C6H16N2
T22500
N,N,N′,N′-Tetramethylethylenediamine, ReagentPlus®, 99%
C6H16N2
P5585
Palmitic acid, BioXtra, ≥99%
C16H32O2
P0500
Palmitic acid, ≥99%
C16H32O2
P0625
Palmitic acid, Grade II, ~95%
C16H32O2
43051
Palmitic acid, certified reference material, TraceCERT®
C16H32O2
1492007
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
C16H32O2
76119
Palmitic acid, analytical standard
C16H32O2
27734
Palmitic acid, ≥98% palmitic acid basis (GC)
C16H32O2
76122
Palmitic acid, purum, ≥98.0% (GC)
C16H32O2
W283207
Palmitic acid, ≥95%, FCC, FG
C16H32O2
PHR1120
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C16H32O2
P0090000
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
C16H32O2
W283215
Palmitic acid, natural, 98%, FG
C16H32O2